HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
Jessica M. Fogel(Johns Hopkins University), Juliet Mpendo(Uganda Virus Research Institute), Joseph Szewczyk(Johns Hopkins University), Myron S. Cohen(University of North Carolina at Chapel Hill), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Deborah Persaud(Johns Hopkins University), Estelle Piwowar‐Manning(Johns Hopkins University), Jennifer Farrior(Family Health International 360), Raphael J. Landovitz(APLA Health), Trần Việt Hà(University of North Carolina at Chapel Hill), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Paul Richardson(University of Liverpool), Carrie‐Anne Mathew(University of the Witwatersrand), Chaiwat Ungsedhapand, Sinéad Delany‐Moretlwe(University of Cape Town), Susan H. Eshleman(Johns Hopkins University), Mark A. Marzinke(Family Health International 360), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alex R. Rinehart, Xu Guo(Fred Hutch Cancer Center), Mina C. Hosseinipour, Zhe Wang(Tsinghua University)
Cited by 5
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891